Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism

Nuclear Medicine and Biology

Volumn 23, Issue 3, 1996, Pages 295-301

  Ishiwata, Kiichi ^a   Shinoda, Masaki ^a,b   Ishii, Shin Ichi ^a   Nozaki, Tadashi ^b   Senda, Michio ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

6 18F fluoro O pivaloyl L dopa; Dopamine metabolism; Positron emission tomography; Prodrug

Indexed keywords

BENZOPHENONE DERIVATIVE; CARBIDOPA; CATECHOL METHYLTRANSFERASE; DIAGNOSTIC AGENT; DOPA; DOPAMINE; DRUG DERIVATIVE; ENZYME INHIBITOR; FLUORINE; FLUORODOPA F 18; NITROPHENOL; PRODRUG; TOLCAPONE; 6 FLUORO O PIVALOYL DOPA; 6 FLUORODOPA; FLUORINE 18; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BIOTRANSFORMATION; BRAIN; BRAIN CORTEX; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE; SYNTHESIS; TIME; TISSUE DISTRIBUTION; ANIMAL EXPERIMENT; BRAIN METABOLISM; CONTROLLED STUDY; DRUG SYNTHESIS; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; BENZOPHENONES; BIOTRANSFORMATION; BRAIN; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CEREBRAL CORTEX; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; ENZYME INHIBITORS; FLUORINE RADIOISOTOPES; INJECTIONS, INTRAVENOUS; MICE; NITROPHENOLS; PRODRUGS; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029665293     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(95)02083-7     Document Type: Article

References (27)

1. 18F]-fluorodopa. J. Label. Compds. Radiopharm. 31, 39-43.
2. 18F]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies. Life Sci. 50, 309-318.
3. 18F-fluorodopa in the hooded rat. Biochem. Pharmacol. 37, 247-250.
4. 18F]6-fluoro-L-3.4-dihydroxyphenylalanine in the hooded rat. J. Neurochem. 48, 601-608.
5. 18F]F-DOPA) in humans. J. Cereb. Blood Flow Metab. 13, 668-675.
6. Dejesus O. T., Sunderland J. J., Nickles J. R., Mukherjee J. and Appelman E. H. (1990) Synthesis of radiofluorinated analogs of m-tyrosine as potential L-dopa tracers via direct reaction with acetylhypofluorite. Appl. Radiat. Isot. 41, 433-437.
7. 18F]fluoro-L-DOPA in the rhesus monkey brain. J. Cereb. Blood Flow Metab. 11, 726-734.
8. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J. Neurochem. 48, 1077-1082.
9. 18F]fluoro-L-dopa in human blood. J. Nucl. Med. 29, 363-369.
10. 18F]fluoro-L-dopa with different enzyme inhibitors. J. Label. Compds. Radiopharm. 35, 480-482 (Abstract).
11. Hisaka A., Kasamatsu S., Takenaga N. and Ohtawa M. (1990) Absorption of a novel prodrug of L-dopa, L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355). Drug Metab. Dispos. 18, 621-625.
12. 18F]fluoro-L-DOPA kinetics in positron emission tomography. J. Nucl. Med. 33, 1472-1477.
13. Ihara M, Nakajima S., Hisaka A., Tsuchiya Y., Sakuma Y., Suzuki H., Kitani K. and Yano M. (1990) Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. J. Pharm. Sci. 79, 703-708.
14. Ihara M., Tsuchiya Y., Sawasaki Y., Hisaka A., Takehana H., Tomimoto K. and Yano M. (1989) A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. J Pharm. Sci. 78, 525-529.
15. Ishiwata K., Ishii S. and Senda M. (1993a) HPLC using physiological saline for the quality control of radiopharmaceuticals used in PET studies. Appl. Radiat. Isot. 44, 1119-1124.
16. 18F]fluoro-L-dopa: Use of 4-O-pivaloyl-L-dopa as a suitable precursor for routine production. Appl. Radiat. Isot. 44, 755-759.
17. 18F]fluorodopa uptake for melanogenesis in murine metastatic melanomas. J. Nucl. Med. 32, 95-101.
18. 18F]-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 42, 199-203.
19. 18F]fluoro-L-dopa plasma input curves with and without carbidopa and in hemi-MPTP lesioned monkeys. Appl. Radiat. Isot. 42, 847-854.
20. 18F]fluoro-DOPA metabolism in monkeys and humans: Biochemical parameters for the formation of tracer kinetic models with positron emission tomography. J. Cereb. Blood Flow Metab. 11, 890-897.
21. 18F]Fluoro-β-fluoromethylene-m-tyrosine analogs, potential PET agents for presynaptic dopamine terminals: Synthesis and spectroscopic characterization. Appl. Radiat. Isot. 43, 969-977.
22. 18F]fluoro-L-m-tyrosine via regioselective radiofluorodestannylation. Appl. Radiat. Isot. 44, 527-536.
23. 18F]-6-L-fluorodopa metabolism: Implications for levedopa therapy of Parkinson's disease. Neurology 44, 1292-1287.
24. 18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol. Scand. 81, 24-30.
25. Tye S. J., Rupniak N. M. J., Naruse T., Miyaji M. and Iversen S. D. (1989) NB-355: A novel prodrug for L-dopa with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys. Clin. Neuropharmacol 12, 393-403.
26. Zur M. and Nemerson Y. (1978) The esterase activity of coagulation factor VII. Evidence for intrinsic activity of the zymogen. J. Biol. Chem. 253, 2203-2209.
27. Zürcher G., Keller H. H., Kettler R., Borgulya J., Bonetti E. P., Eigenman R. and Da Parada M. (1990) RO 40-7592, a novel, very potent and orally active inhibitor of catechol-O-methyltransferase: A pharmacological study in rats. Adv. Neurol. 53, 497-503.